Management of ventricular and atrial arrhythmias in humans: towards a patient-specific approach

Area of Science:

• Cardiology
• Pharmacology

Background:

• Current strategies for sudden cardiac death (SCD) prevention, primarily using implantable cardioverter defibrillators (ICDs), rely heavily on ejection fraction, lacking patient specificity.
• A significant number of ICD recipients do not receive shocks, indicating suboptimal selection criteria and potential for cost savings through improved patient stratification.
• Atrial fibrillation (AF) management faces challenges with antiarrhythmic drugs, particularly in patients with co-existing heart failure, necessitating tailored therapeutic approaches.

Purpose of the Study:

• To review and contrast the current approaches to sudden cardiac death prevention and atrial fibrillation management.
• To highlight the limitations of broad patient selection criteria in ICD implantation and antiarrhythmic drug therapy.
• To emphasize the critical need for patient-specific strategies in cardiovascular disease management.

Main Methods:

• Review of existing literature and clinical trial data concerning ICD implantation for primary prevention of SCD.
• Analysis of antiarrhythmic drug efficacy and safety in atrial fibrillation, with a focus on heart failure patients.
• Case study of Dronedarone's development and trial outcomes (ATHENA, PALLAS) to illustrate patient-specific challenges.

Main Results:

• Ejection fraction, while a common metric for ICDs, demonstrates low positive predictive value, leading to unnecessary implants.
• Antiarrhythmic drugs for AF are effective only when contraindications are strictly observed, especially in heart failure patients.
• Dronedarone trials revealed benefits in certain heart disease patients but contraindications in those with advanced heart failure, underscoring the need for precise patient selection.

Conclusions:

• A paradigm shift towards patient-specific selection criteria is essential for both ICD implantation in SCD prevention and antiarrhythmic drug therapy in AF.
• Implementing personalized medicine approaches can optimize therapeutic outcomes, reduce healthcare costs, and improve patient safety.
• The dichotomy in current strategies necessitates a move towards more refined, individualized treatment plans in cardiovascular care.